Skip to main content
TipRanks
Go Ultimate75% OFF

Journey Medical Corp (DERM) AI Stock Analysis

122 Followers
DERM

Journey Medical Corp

(NASDAQ:DERM)

Select Model
Rating:47Neutral
Price Target:$4.50▲(3.93% Upside)
Action:reiterated
Date:11/14/26

The score is primarily held back by transitional financial quality (ongoing net losses and negative free cash flow) and weak technicals (price below major moving averages with negative MACD). These risks are partially offset by constructive earnings-call momentum—improving commercial execution, positive EBITDA quarters, and expected payer-access catalysts into 2027—while valuation provides limited support due to negative earnings and no dividend data.

Positive Factors
Revenue and EBITDA improvementStronger revenue, gross margin, and EBITDA performance indicates improving operating execution rather than growth alone. If product sales continue expanding faster than expenses, Journey Medical could build a more durable path toward earnings and cash-flow breakeven.
Negative Factors
Persistent GAAP lossesThe continued GAAP loss shows that improved commercial activity has not yet translated into sustainable bottom-line profitability. Ongoing losses can limit internally funded investment and may continue weighing on financial resilience until operating income consistently turns positive.

Journey Medical Corp (DERM) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%30%DERM-43.40%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$122.21M
Dividend Yield
―
Average Volume (3M)
183.60K
Price to Earnings (P/E)
-23.3
Beta (1Y)
0.59
Revenue Growth
17.03%
EPS Growth
49.40%
Country
US
Employees
58
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Journey Medical Corp Business Overview & Revenue Model

Company Description

Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the U...

Journey Medical Corp Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:-1.37%|Next Earnings Date:Mar 31, 2027
Earnings Call SentimentPositive

The call was predominantly positive, marked by revenue and net product sales growth, improving gross margin, two consecutive quarters of positive EBITDA, strong Emrosi prescription and prescriber expansion, favorable refill trends, compelling clinical data, and expected payer-access improvements. The company still reported a GAAP loss, a lower cash balance, one-time vendor settlement costs, temporary prescription volatility following a copay change, and incomplete formulary coverage, but management characterized these issues as manageable or nonrecurring while emphasizing continued commercial momentum.

Positive Updates

Revenue Growth and Improved Profitability
Third-quarter total revenue was $19 million versus $15 million in the third quarter of 2025, with management reporting 8% year-over-year growth. Net product sales increased 11% year-over-year, gross margin improved to 69% from 67%, and the company achieved positive EBITDA for the second consecutive quarter.

Negative Updates

One-Time Vendor Settlement Expense
SG&A expenses were $12.6 million versus $12.1 million in the third quarter of 2025, primarily due to a $1.7 million one-time expense related to the settlement of a dispute with a former vendor. Management said the settlement was a one-time cash outlay and is now fully resolved.

Company Guidance

Management expects Emrosi’s key metrics to “continue to trend positively in the coming quarters,” ASP to “trend higher in the coming quarters,” and high-quality coverage to increase from “40% of commercial lives,” or about “170 million, 180 million lives,” after a large national plan covering “over 25 million lives” takes effect at the beginning of 2027; quality coverage means “a single-step or better.” Management expects the plan’s impact to be felt “beginning in Q1,” anticipates an “upward trend on ASP and improvement in gross-to-net as the quarters progress in '27,” expects newly added representatives to have “a good 2 quarters” to become productive, and said prescription volatility after the copay change might take “anywhere from 4 to 8 weeks” to recover. SG&A is expected to be “consistent or a little bit lower as a percentage of revenue,” while management is “probably going to be somewhat apprehensive here in the first half of next year to give any particular guidance” on 2027 revenue or EBITDA.

Journey Medical Corp Financial Statement Overview

Summary

Financials show a rebound with very strong TTM revenue growth and improving profitability (EBITDA turning positive), and leverage appears manageable. However, the company is still reporting net losses and the cash flow profile is the key weakness, with TTM operating cash flow and free cash flow remaining negative.

Income Statement

44Neutral

Balance Sheet

56Neutral

Cash Flow

32Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue69.52M61.86M56.13M79.18M73.67M63.13M
Gross Profit30.03M36.68M35.26M52.52M42.89M31.05M
EBITDA2.74M-3.33M-8.40M1.92M-23.18M-32.77M
Net Income-5.10M-11.43M-14.67M-3.85M-29.63M-43.99M
Balance Sheet
Total Assets103.85M94.59M80.24M76.85M105.16M97.28M
Cash, Cash Equivalents and Short-Term Investments22.32M24.09M20.30M27.44M32.00M49.08M
Total Debt25.62M25.40M25.70M17.73M22.96M9.05M
Total Liabilities71.60M62.74M60.17M56.50M88.18M55.24M
Stockholders Equity32.25M31.85M20.07M20.35M16.98M42.04M
Cash Flow
Free Cash Flow-8.55M-12.44M-24.13M240.00K-33.53M-12.18M
Operating Cash Flow-8.55M-12.44M-9.13M5.24M-13.53M-2.18M
Investing Cash Flow00-15.00M-5.00M-20.00M-10.00M
Financing Cash Flow5.92M16.23M16.99M-4.80M16.46M53.02M

Journey Medical Corp Technical Analysis

Technical Analysis SentimentNegative
Last Price4.33

Price Trends

50DMA5.89Negative
100DMA6.40Negative
200DMA6.44Negative

Market Momentum

MACD-0.42Negative
RSI33.33Neutral
STOCH21.16Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DERM, the sentiment is Negative. The current price of 4.33 is below the 20-day moving average (MA) of 4.80, below the 50-day MA of 5.89, and below the 200-day MA of 6.44, indicating a bearish trend. The MACD of -0.42 indicates Negative momentum. The RSI at 33.33 is Neutral, neither overbought nor oversold. The STOCH value of 21.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DERM.

Journey Medical Corp Risk Analysis

Journey Medical Corp disclosed 62 risk factors in its most recent earnings report. Journey Medical Corp reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.There is substantial doubt regarding our ability to continue as a going concern. We may need to raise additional funding (which may not be available on acceptable terms to the Company, or at all) and/or to delay, limit or terminate certain of our product development and commercialization efforts or other operations.Q4, 2023
2.If the FDA does not conclude that a product candidate satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for such product candidate under Section 505(b)(2) are not as we expect, the approval pathway for the product candidate will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.Q4, 2023
3.Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition or results of operations.Q4, 2023

Journey Medical Corp Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DERM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TKNOTKNO56Neutral$516.43M-27.83-24.95%―15.45%12.64%
CPIXCPIX53Neutral$88.10M1.28202.58%23.57%-39.11%-241.27%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TLPHTLPH49Neutral$47.07M-3.50-96.70%―-100.00%46.24%
DERMDERM47Neutral$122.21M-23.29-16.07%―17.03%49.40%

* Healthcare Sector Average

Performance Comparison

0%200%400%DERMTLPHCPIXSXTCTKNODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DERM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DERMJourney Medical Corporation4.33-3.62-45.53%
TLPHTalphera, Inc.0.91-0.43-32.39%
CPIXCumberland Pharmaceuticals Inc.5.884.35285.07%
SXTCChina Sxt Pharmaceuticals3.00-1919997.00-100.00%
TKNOAlpha Teknova, Inc.8.213.8086.17%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026